---
document_datetime: 2025-12-02 05:26:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma.html
document_name: dasatinib-accordpharma.html
version: success
processing_time: 0.108969
conversion_datetime: 2025-12-28 13:25:44.489578
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dasatinib Accordpharma

[RSS](/en/individual-human-medicine.xml/67544)

##### Withdrawn

This medicine's authorisation has been withdrawn

dasatinib (anhydrous) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dasatinib Accordpharma](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 25 March 2023, the European Commission withdrew the marketing authorisation for Dasatinib Accordpharma (dasatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Accord Healthcare S.L.U., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Dasatinib Accordpharma was granted marketing authorisation in the EU on 24 March 2022 for the treatment of leukaemia.

The product had not been marketed in the EU. Dasatinib Accordpharma is a generic medicine of Sprycel.

The European Public Assessment Report (EPAR) for Dasatinib Accordpharma is updated to indicate that the marketing authorisation is no longer valid.

Dasatinib Accordpharma : EPAR - Medicine Overview

Reference Number: EMA/124603/2022

English (EN) (758.43 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 30/03/2023

[View](/en/documents/overview/dasatinib-accordpharma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-557)

български (BG) (831.72 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/bg/documents/overview/dasatinib-accordpharma-epar-medicine-overview_bg.pdf)

español (ES) (739.29 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/es/documents/overview/dasatinib-accordpharma-epar-medicine-overview_es.pdf)

čeština (CS) (812.88 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/cs/documents/overview/dasatinib-accordpharma-epar-medicine-overview_cs.pdf)

dansk (DA) (737.09 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/da/documents/overview/dasatinib-accordpharma-epar-medicine-overview_da.pdf)

Deutsch (DE) (742.86 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/de/documents/overview/dasatinib-accordpharma-epar-medicine-overview_de.pdf)

eesti keel (ET) (725.05 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/et/documents/overview/dasatinib-accordpharma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (834.34 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/el/documents/overview/dasatinib-accordpharma-epar-medicine-overview_el.pdf)

français (FR) (740.47 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fr/documents/overview/dasatinib-accordpharma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (761.27 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hr/documents/overview/dasatinib-accordpharma-epar-medicine-overview_hr.pdf)

italiano (IT) (736.65 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/it/documents/overview/dasatinib-accordpharma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (821.97 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lv/documents/overview/dasatinib-accordpharma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (761.43 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lt/documents/overview/dasatinib-accordpharma-epar-medicine-overview_lt.pdf)

magyar (HU) (810.55 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hu/documents/overview/dasatinib-accordpharma-epar-medicine-overview_hu.pdf)

Malti (MT) (813.45 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/mt/documents/overview/dasatinib-accordpharma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (739.5 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/nl/documents/overview/dasatinib-accordpharma-epar-medicine-overview_nl.pdf)

polski (PL) (810.27 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pl/documents/overview/dasatinib-accordpharma-epar-medicine-overview_pl.pdf)

português (PT) (738.4 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pt/documents/overview/dasatinib-accordpharma-epar-medicine-overview_pt.pdf)

română (RO) (762.37 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/ro/documents/overview/dasatinib-accordpharma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (809.58 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sk/documents/overview/dasatinib-accordpharma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (806.56 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sl/documents/overview/dasatinib-accordpharma-epar-medicine-overview_sl.pdf)

Suomi (FI) (735.19 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fi/documents/overview/dasatinib-accordpharma-epar-medicine-overview_fi.pdf)

svenska (SV) (736.87 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sv/documents/overview/dasatinib-accordpharma-epar-medicine-overview_sv.pdf)

Dasatinib Accordpharma : EPAR - Risk management plan summary

English (EN) (701.15 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 30/03/2023

[View](/en/documents/rmp-summary/dasatinib-accordpharma-epar-risk-management-plan-summary_en.pdf)

## Product information

Dasatinib Accordpharma : EPAR - Product Information

English (EN) (1.72 MB - PDF)

**First published:** 30/03/2022

**Last updated:** 30/03/2023

[View](/en/documents/product-information/dasatinib-accordpharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-834)

български (BG) (3.32 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/bg/documents/product-information/dasatinib-accordpharma-epar-product-information_bg.pdf)

español (ES) (1.51 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/es/documents/product-information/dasatinib-accordpharma-epar-product-information_es.pdf)

čeština (CS) (2.66 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/cs/documents/product-information/dasatinib-accordpharma-epar-product-information_cs.pdf)

dansk (DA) (1.82 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/da/documents/product-information/dasatinib-accordpharma-epar-product-information_da.pdf)

Deutsch (DE) (1.84 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/de/documents/product-information/dasatinib-accordpharma-epar-product-information_de.pdf)

eesti keel (ET) (1.69 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/et/documents/product-information/dasatinib-accordpharma-epar-product-information_et.pdf)

ελληνικά (EL) (3.76 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/el/documents/product-information/dasatinib-accordpharma-epar-product-information_el.pdf)

français (FR) (1.71 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fr/documents/product-information/dasatinib-accordpharma-epar-product-information_fr.pdf)

hrvatski (HR) (1.92 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hr/documents/product-information/dasatinib-accordpharma-epar-product-information_hr.pdf)

íslenska (IS) (1.69 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/is/documents/product-information/dasatinib-accordpharma-epar-product-information_is.pdf)

italiano (IT) (1.54 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/it/documents/product-information/dasatinib-accordpharma-epar-product-information_it.pdf)

latviešu valoda (LV) (2.76 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lv/documents/product-information/dasatinib-accordpharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.02 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lt/documents/product-information/dasatinib-accordpharma-epar-product-information_lt.pdf)

magyar (HU) (2.93 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hu/documents/product-information/dasatinib-accordpharma-epar-product-information_hu.pdf)

Malti (MT) (3.05 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/mt/documents/product-information/dasatinib-accordpharma-epar-product-information_mt.pdf)

Nederlands (NL) (1.67 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/nl/documents/product-information/dasatinib-accordpharma-epar-product-information_nl.pdf)

norsk (NO) (1.78 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/no/documents/product-information/dasatinib-accordpharma-epar-product-information_no.pdf)

polski (PL) (2.91 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pl/documents/product-information/dasatinib-accordpharma-epar-product-information_pl.pdf)

português (PT) (1.69 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pt/documents/product-information/dasatinib-accordpharma-epar-product-information_pt.pdf)

română (RO) (1.82 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/ro/documents/product-information/dasatinib-accordpharma-epar-product-information_ro.pdf)

slovenčina (SK) (2.79 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sk/documents/product-information/dasatinib-accordpharma-epar-product-information_sk.pdf)

slovenščina (SL) (3 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sl/documents/product-information/dasatinib-accordpharma-epar-product-information_sl.pdf)

Suomi (FI) (1.64 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fi/documents/product-information/dasatinib-accordpharma-epar-product-information_fi.pdf)

svenska (SV) (1.85 MB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sv/documents/product-information/dasatinib-accordpharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0001 22/06/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dasatinib Accordpharma : EPAR - All authorised presentations

English (EN) (650.38 KB - PDF)

**First published:** 30/03/2022

**Last updated:** 30/03/2023

[View](/en/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-621)

български (BG) (708.94 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/bg/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (659.39 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/es/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (674.23 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/cs/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (653.86 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/da/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (653.15 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/de/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (651.72 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/et/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (720.35 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/el/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_el.pdf)

français (FR) (659.68 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fr/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (678.48 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hr/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (651.12 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/is/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (651.34 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/it/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (713.23 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lv/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (675.73 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/lt/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (703.71 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/hu/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (702.9 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/mt/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (651.46 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/nl/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (651.33 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/no/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (693.49 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pl/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (663.41 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/pt/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (660.5 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/ro/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (694.45 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sk/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (711.26 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sl/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (652.41 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/fi/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (651.68 KB - PDF)

**First published:**

30/03/2022

**Last updated:**

30/03/2023

[View](/sv/documents/all-authorised-presentations/dasatinib-accordpharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dasatinib Accordpharma Active substance dasatinib International non-proprietary name (INN) or common name dasatinib (anhydrous) Therapeutic area (MeSH)

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Anatomical therapeutic chemical (ATC) code L01EA02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Dasatinib Accordpharma is indicated for the treatment of adult patients with:

- newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
- chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.
- Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
- Dasatinib Accordpharma is indicated for the treatment of paediatric patients with:
- newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
- newly diagnosed Ph+ ALL in combination with chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/005317

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 27/01/2022 Marketing authorisation issued 24/03/2022 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dasatinib Accordpharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (682.28 KB - PDF)

**First published:** 24/10/2022

**Last updated:** 30/03/2023

[View](/en/documents/procedural-steps-after/dasatinib-accordpharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Dasatinib Accordpharma : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/117327/2022

English (EN) (1.39 MB - PDF)

**First published:** 30/03/2022

**Last updated:** 30/03/2023

[View](/en/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Dasatinib Accordpharma

Adopted

Reference Number: EMA/CHMP/10901/2022

English (EN) (710.64 KB - PDF)

**First published:** 28/01/2022

**Last updated:** 30/03/2023

[View](/en/documents/smop-initial/chmp-summary-opinion-dasatinib-accordpharma_en.pdf)

#### News on Dasatinib Accordpharma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

**This page was last updated on** 30/03/2023

## Share this page

[Back to top](#main-content)